ATE301192T1 - Verwendung von neuronalem apoptose- inhibitorprotein - Google Patents

Verwendung von neuronalem apoptose- inhibitorprotein

Info

Publication number
ATE301192T1
ATE301192T1 AT97902522T AT97902522T ATE301192T1 AT E301192 T1 ATE301192 T1 AT E301192T1 AT 97902522 T AT97902522 T AT 97902522T AT 97902522 T AT97902522 T AT 97902522T AT E301192 T1 ATE301192 T1 AT E301192T1
Authority
AT
Austria
Prior art keywords
inhibitor protein
apoptosis inhibitor
neuronal apoptosis
naip
apoptosis
Prior art date
Application number
AT97902522T
Other languages
English (en)
Inventor
Robert G Korneluk
Alexander E Mackenzie
Natalie Roy
George Robertson
Katsu Tamai
Original Assignee
Univ Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ottawa filed Critical Univ Ottawa
Application granted granted Critical
Publication of ATE301192T1 publication Critical patent/ATE301192T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
AT97902522T 1996-01-19 1997-01-17 Verwendung von neuronalem apoptose- inhibitorprotein ATE301192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601108.5A GB9601108D0 (en) 1996-01-19 1996-01-19 Neuronal apoptosis inhibitor protein (NAIP)
PCT/IB1997/000142 WO1997026331A2 (en) 1996-01-19 1997-01-17 Use of neuronal apoptosis inhibitor protein (naip)

Publications (1)

Publication Number Publication Date
ATE301192T1 true ATE301192T1 (de) 2005-08-15

Family

ID=10787268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97902522T ATE301192T1 (de) 1996-01-19 1997-01-17 Verwendung von neuronalem apoptose- inhibitorprotein

Country Status (11)

Country Link
US (2) US6994957B2 (de)
EP (2) EP1609864A3 (de)
JP (1) JP4005135B2 (de)
AT (1) ATE301192T1 (de)
AU (1) AU1614997A (de)
CA (1) CA2215793C (de)
DE (1) DE69733861T2 (de)
DK (1) DK0815231T3 (de)
ES (1) ES2245790T3 (de)
GB (1) GB9601108D0 (de)
WO (1) WO1997026331A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
GB9601108D0 (en) * 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
ATE398459T1 (de) * 1996-04-26 2008-07-15 Univ Ottawa Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
JPH11116599A (ja) * 1997-10-14 1999-04-27 Japan Science & Technology Corp アポトーシス抑制蛋白質とこの蛋白質をコードする 遺伝子およびそのcDNA
US6171821B1 (en) 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
JP2000125861A (ja) * 1998-10-26 2000-05-09 Japan Science & Technology Corp ヒト・アポトーシス抑制蛋白質naipに対する モノクローナル抗体と、naipの検定方法
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
NZ546806A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2006051757A1 (ja) * 2004-11-10 2006-05-18 Neugen Pharma, Inc 虚血性心疾患もしくは虚血性心筋症の治療剤または予防剤
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
KR101779370B1 (ko) 2016-06-29 2017-09-19 한국수력원자력 주식회사 방사선 조사 된 흉선 림프종 세포에서 발굴 된 세포고사 조절 유전자 및 그 검출방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123406A1 (en) 1992-09-14 1994-03-31 Katia Georgopoulos Ikaros: a t cell pathway regulatory gene
CA2681922C (en) 1994-01-18 2012-05-15 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6020127A (en) 1994-10-18 2000-02-01 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US5919912A (en) 1995-08-04 1999-07-06 University Of Ottawa Mammalian IAP antibodies and diagnostic kits
GB9601108D0 (en) 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases

Also Published As

Publication number Publication date
JPH11503620A (ja) 1999-03-30
US20020137028A1 (en) 2002-09-26
US6994957B2 (en) 2006-02-07
CA2215793A1 (en) 1997-07-24
EP1609864A3 (de) 2007-12-12
ES2245790T3 (es) 2006-01-16
WO1997026331A3 (en) 1997-10-02
GB9601108D0 (en) 1996-03-20
WO1997026331A2 (en) 1997-07-24
EP0815231B1 (de) 2005-08-03
EP1609864A2 (de) 2005-12-28
US7235372B2 (en) 2007-06-26
CA2215793C (en) 2005-07-05
JP4005135B2 (ja) 2007-11-07
DE69733861D1 (de) 2005-09-08
DE69733861T2 (de) 2006-05-24
EP0815231A2 (de) 1998-01-07
AU1614997A (en) 1997-08-11
US20060172348A1 (en) 2006-08-03
DK0815231T3 (da) 2005-12-12

Similar Documents

Publication Publication Date Title
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
DE69733861D1 (de) Verwendung von neuronalem apoptose-inhibitorprotein
ATE529509T1 (de) Selektion von proteinen unter verwendung von rna- protein-fusionen
DE69434614D1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
EP0892048A3 (de) XAF Gene und Polypeptide und deren Verwendung zur Modulation der Apoptose
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
EP1032837A4 (de) Zielsequenzen für synthetische moleküle und verfahren für deren verwendung
DE69731038D1 (de) Screening-test zur identifikation von inhibitoren des makrophagenmigrationshemmenden faktors
DE60334246D1 (de) Modulieren von immunantworten
DE69222710T2 (de) Verfahren zum Nachweis von DNS-Basen mit Verwendung von Fluoreszenz
NO20010389L (no) Modulering av multippel linje kinase proteiner
DE69606837D1 (de) Gerät zur Überprüfung der Bestimmungen von klinischen Analysen
WO2000047102A3 (en) COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING
DE69807148T2 (de) Verfahren zur Hydroformylierung von Olefininen
ATE219515T1 (de) Methoden und reagenzien zur regulierung von apoptosis
DE59910237D1 (de) Verfahren zur automatischen taktfreien Erkennung von Signal-Modulationsarten
DK1007649T3 (da) Fremgangsmåder til screening for interaktioner mellem transkriptionsfaktor og coaktivator
DE69719726T2 (de) Verfahren zur Detektion von Leukämie
DE69714424D1 (de) Verwendung von kolostrum zur behandlung von darmverstopfung
ES2102776T3 (es) Inhibidores de la fosfolipasa a2.
WO2001020335A3 (en) Methods for modulating cell proliferation
DE69527559D1 (de) Verfahren zur Positionsbestimmung von Sendern
DE59504158D1 (de) Verwendung sulfierter substanzen zur fettung von leder

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties